**Abstract**

**Background/Objectives:** Antidepressants are often used in conjunction with anti-Alzheimer drugs to treat the behavioral and psychological symptoms of dementia (BPSD). Here, we studied the interactions between anti-Alzheimer drugs, cholinesterase inhibitors (ChEIs), and antidepressants in inducing extrapyramidal side effects (EPS).

**Methods:** Male ddY mice were used. Using the pole test, we examined the actions of serotonin reuptake inhibitors (SSRIs), fluoxetine and paroxetine, a serotonin and noradrenaline reuptake inhibitor (SNRI) milnacipran, a noradrenergic and specific serotonergic **antidepressant (NaSSA)** mirtazapine in modulating the ChEIs (galantamine and donepezil)-induced bradykinesia.

**Results:** Both fluoxetine and paroxetine significantly potentiated galantamine-induced bradykinesia in a synergistic manner. The EPS augmentation by fluoxetine was antagonized by ketanserin (5-HT~2~ antagonist) and SB-258585 (5-HT~6~ antagonist), but not by ondansetron (5-HT~3~ antagonist). In contrast to SSRIs, milnacipran and mirtazapine failed to augment galantamine-induced EPS. In addition, combined treatment of prazosin (α~1~ antagonist), but not yohimbine (α~2~ antagonist), with milnacipran significantly potentiated galantamine-induced EPS.

**Conclusion:** The present results indicate that SSRIs and ChEIs synergistically facilitate the EPS induction, via the activation of 5-HT~2~ and 5-HT~6~ receptors, in the treatment of BPSD. The combination of ChEIs with SNRIs (or **NaSSA)** is recommended in terms of EPS liability for the BPSD therapy, where the activation of α~1~ receptors by SNRIs seems to reduce EPS.
